Courtagen Submits Pre-IDE to FDA for C-reactive Protein Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said it has submitted its first pre-investigational device exemption information package to US regulators for its automated solution for measuring C-reactive proteins in a clinical setting.

In addition to its submission to the US Food and Drug Administration, Courtagen is pursuing a CE Mark for the solution, which is comprised of its Avantra Q400 BioMarker Workstation and the QPDx BioChip.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.